Literature DB >> 17467843

Relationship between proinsulin-to-insulin ratio and advanced glycation endproducts in Japanese type 2 diabetic subjects.

Yoshifumi Saisho1, Taro Maruyama, Hiroshi Hirose, Takao Saruta.   

Abstract

OBJECTIVE: Type 2 diabetes (T2DM) is characterized by increased proinsulin-to-insulin ratio (P/I ratio), increased glycation and oxidative stress, and beta-cell dysfunction. Previous reports implicated that increased P/I ratio, glycation and oxidative stress constitute markers of beta-cell dysfunction in T2DM. However, its clinical relevance remains to be elucidated. Therefore, in the present study we investigated the relationship between the P/I ratio, glycation and oxidative stress markers in patients with T2DM, using newly developed intact chemiluminescent immunoassay for proinsulin.
METHODS: Fasting intact proinsulin, insulin, advanced glycation endproducts (AGEs), pentosidine, lipid peroxide and urine 8-isoprostane as well as other metabolic parameters were measured in 64 T2DM subjects.
RESULTS: Using univariate analysis, P/I ratio showed significant positive correlations with plasma glucose (r=0.465), HbA1c (r=0.434) and AGEs (r=0.282), and significant negative correlations with insulin (r=-0.330) and HOMA-beta (r=-0.520) even after adjustment for age, sex, duration of diabetes, family history of diabetes, use of sulfonylureas, smoking and body mass index. Additionally, stepwise multiple regression analysis revealed that HOMA-beta, HbA1c and AGEs were independently and significantly correlated with P/I ratio.
CONCLUSION: These findings suggest that not only hyperglycemia per se but also glycation is involved in beta-cell dysfunction in T2DM subjects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17467843     DOI: 10.1016/j.diabres.2007.03.014

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  6 in total

1.  AGEs decrease insulin synthesis in pancreatic β-cell by repressing Pdx-1 protein expression at the post-translational level.

Authors:  Tingting Shu; Yunxia Zhu; Hongdong Wang; Yan Lin; Zhuo Ma; Xiao Han
Journal:  PLoS One       Date:  2011-04-18       Impact factor: 3.240

2.  Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.

Authors:  Jin Lu; Jiajie Zang; Huihua Li
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

3.  Liraglutide ameliorates beta-cell function, alleviates oxidative stress and inhibits low grade inflammation in young patients with new-onset type 2 diabetes.

Authors:  Wen-Qiang Zhang; Yuan Tian; Xiao-Min Chen; Li-Fen Wang; Chan-Chan Chen; Chuan-Mei Qiu
Journal:  Diabetol Metab Syndr       Date:  2018-12-17       Impact factor: 3.320

4.  Prominent Hyperproinsulinemia in a Middle Age Patient.

Authors:  Hiroshi Yoshino; Kyoko Kawakami; Kei Yoshino; Gen Yoshino
Journal:  Clin Med Insights Case Rep       Date:  2021-09-01

Review 5.  Update on the protective molecular pathways improving pancreatic beta-cell dysfunction.

Authors:  Alessandra Puddu; Roberta Sanguineti; François Mach; Franco Dallegri; Giorgio Luciano Viviani; Fabrizio Montecucco
Journal:  Mediators Inflamm       Date:  2013-05-02       Impact factor: 4.711

6.  Clinical study of advanced glycation end products in egyptian diabetic obese and non-obese patients.

Authors:  Mohamed N Amin; Amany A Mosa; Mamdouh M El-Shishtawy
Journal:  Int J Biomed Sci       Date:  2011-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.